University of California Files Tumor-Neoantigen Antibody Patents for Cancer
Summary
The Regents of the University of California filed patent application US20260109786A1 on April 23, 2026, covering chemically controlled monoclonal antibodies reactive with tumor-specific neoantigens and neoantigen-binding fragments. The application also discloses related nucleic acids, expression cassettes, and expression vectors encoding the antibodies. Inventors include Charles S. CRAIK, Kevan M. SHOKAT, Ziyang ZHANG, and Peter J. ROHWEDER. The antibodies and fragments are disclosed as useful for cancer diagnosis and treatment.
“The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
The University of California filed a patent application (US20260109786A1) with the USPTO disclosing antibodies reactive with tumor-specific neoantigens, along with encoding nucleic acids and expression vectors. The application claims priority to filing date November 10, 2025, under Application No. 19384963. CPC classifications include C07K 16/44, C07K 16/2809, A61K 39/39558, and related pharmaceutical composition codes.
Entities in the biotechnology and pharmaceutical sectors should monitor this published application to assess potential freedom-to-operate considerations if developing similar antibody-based cancer therapeutics. The published claims, once examined, may affect licensing negotiations and competitive product development in the neoantigen-targeted therapy space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
Application US20260109786A1 Kind: A1 Apr 23, 2026
Assignee
The Regents of the University of California
Inventors
Charles S. CRAIK, Kevan M. SHOKAT, Ziyang ZHANG, Peter J. ROHWEDER
Abstract
The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.
CPC Classifications
C07K 16/44 A61K 39/39558 A61K 39/39583 A61K 47/50 A61K 47/6843 A61P 35/00 C07K 16/2809 G01N 33/575 A61K 2039/505 C07K 2317/21 C07K 2317/24 C07K 2317/31 C07K 2317/55 C07K 2317/565 C07K 2317/92
Filing Date
2025-11-10
Application No.
19384963
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.